Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia
Abstract It was previously reported that PRR34‐AS1 was overexpressed in some solid tumors. PRR34‐AS1 promoter was shown to have a differential methylation region (DMR), and was hypomethylated in acute myeloid leukemia (AML). Therefore, the present study used real‐time quantitative PCR (RQ‐PCR) to ex...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4085 |
| _version_ | 1819109039001305088 |
|---|---|
| author | Fang‐yu Nan Yu Gu Zi‐jun Xu Guo‐kang Sun Jing‐dong Zhou Ting‐juan Zhang Ji‐chun Ma Jia‐yan Leng Jiang Lin Jun Qian |
| author_facet | Fang‐yu Nan Yu Gu Zi‐jun Xu Guo‐kang Sun Jing‐dong Zhou Ting‐juan Zhang Ji‐chun Ma Jia‐yan Leng Jiang Lin Jun Qian |
| author_sort | Fang‐yu Nan |
| collection | DOAJ |
| description | Abstract It was previously reported that PRR34‐AS1 was overexpressed in some solid tumors. PRR34‐AS1 promoter was shown to have a differential methylation region (DMR), and was hypomethylated in acute myeloid leukemia (AML). Therefore, the present study used real‐time quantitative PCR (RQ‐PCR) to explore the expression characteristics of PRR34‐AS1 in AML. In addition, the correlation between the expression of PRR34‐AS1 and clinical prognosis of AML was determined. The findings of this study indicated that high PRR34‐AS1 expression was bound up with shorter overall survival (OS) in AML patients (p = 0.002). Moreover, patients with high expression of PRR34‐AS1 had significantly lower complete remission (CR) rate compared with those with low expression of PRR34‐AS1 after induction chemotherapy. Furthermore, multivariate analysis confirmed that PRR34‐AS1 expression was an independent factor affecting CR in whole‐AML, non‐APL‐AML, and CN‐AML patients (p = 0.032, 0.039, and 0.036, respectively). Methylation‐specific PCR (MSP) and bisulfite sequencing PCR (BSP) were used to explore the methylation status of PRR34‐AS1. PRR34‐AS1 promoter showed a pattern of hypomethylation in AML patients compared with normal controls (p = 0.122). Notably, of whole‐AML and non‐APL‐AML patients, PRR34‐AS1 hypomethylated patients presented a significantly shorter OS than those with a hypermethylated PRR34‐AS1 (p = 0.010 and 0.037, respectively). Multivariate analysis confirmed that the hypomethylation of PRR34‐AS1 served as an independent prognostic indicator in both whole‐cohort AML and non‐APL‐AML categories (p = 0.057 and 0.018, respectively). In summary, the findings of this study showed that abnormalities in PRR34‐AS1 are associated with poor prognosis in AML. Therefore, monitoring this index may be important in the prognosis of AML and can provide information on effective chemotherapy against the disease. |
| first_indexed | 2024-12-22T03:19:29Z |
| format | Article |
| id | doaj.art-26a63a9512b34fd389ce93ac4210363b |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-22T03:19:29Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-26a63a9512b34fd389ce93ac4210363b2022-12-21T18:40:46ZengWileyCancer Medicine2045-76342021-08-0110155283529610.1002/cam4.4085Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemiaFang‐yu Nan0Yu Gu1Zi‐jun Xu2Guo‐kang Sun3Jing‐dong Zhou4Ting‐juan Zhang5Ji‐chun Ma6Jia‐yan Leng7Jiang Lin8Jun Qian9Department of Hematology Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaDepartment of Hematology Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaLaboratory Center Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaWest China School of Public Health and China Fourth Hospital Sichuan University Chengdu Sichuan People’s Republic of ChinaDepartment of Hematology Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaDepartment of Hematology Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaLaboratory Center Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaDepartment of Hematology Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaLaboratory Center Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaDepartment of Hematology Affiliated People’s Hospital of Jiangsu University Zhenjiang Jiangsu People’s Republic of ChinaAbstract It was previously reported that PRR34‐AS1 was overexpressed in some solid tumors. PRR34‐AS1 promoter was shown to have a differential methylation region (DMR), and was hypomethylated in acute myeloid leukemia (AML). Therefore, the present study used real‐time quantitative PCR (RQ‐PCR) to explore the expression characteristics of PRR34‐AS1 in AML. In addition, the correlation between the expression of PRR34‐AS1 and clinical prognosis of AML was determined. The findings of this study indicated that high PRR34‐AS1 expression was bound up with shorter overall survival (OS) in AML patients (p = 0.002). Moreover, patients with high expression of PRR34‐AS1 had significantly lower complete remission (CR) rate compared with those with low expression of PRR34‐AS1 after induction chemotherapy. Furthermore, multivariate analysis confirmed that PRR34‐AS1 expression was an independent factor affecting CR in whole‐AML, non‐APL‐AML, and CN‐AML patients (p = 0.032, 0.039, and 0.036, respectively). Methylation‐specific PCR (MSP) and bisulfite sequencing PCR (BSP) were used to explore the methylation status of PRR34‐AS1. PRR34‐AS1 promoter showed a pattern of hypomethylation in AML patients compared with normal controls (p = 0.122). Notably, of whole‐AML and non‐APL‐AML patients, PRR34‐AS1 hypomethylated patients presented a significantly shorter OS than those with a hypermethylated PRR34‐AS1 (p = 0.010 and 0.037, respectively). Multivariate analysis confirmed that the hypomethylation of PRR34‐AS1 served as an independent prognostic indicator in both whole‐cohort AML and non‐APL‐AML categories (p = 0.057 and 0.018, respectively). In summary, the findings of this study showed that abnormalities in PRR34‐AS1 are associated with poor prognosis in AML. Therefore, monitoring this index may be important in the prognosis of AML and can provide information on effective chemotherapy against the disease.https://doi.org/10.1002/cam4.4085acute myeloid leukemiaDNA methylationexpressionlncRNAsprognosisPRR34‐AS1 |
| spellingShingle | Fang‐yu Nan Yu Gu Zi‐jun Xu Guo‐kang Sun Jing‐dong Zhou Ting‐juan Zhang Ji‐chun Ma Jia‐yan Leng Jiang Lin Jun Qian Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia Cancer Medicine acute myeloid leukemia DNA methylation expression lncRNAs prognosis PRR34‐AS1 |
| title | Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia |
| title_full | Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia |
| title_fullStr | Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia |
| title_full_unstemmed | Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia |
| title_short | Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia |
| title_sort | abnormal expression and methylation of prr34 as1 are associated with adverse outcomes in acute myeloid leukemia |
| topic | acute myeloid leukemia DNA methylation expression lncRNAs prognosis PRR34‐AS1 |
| url | https://doi.org/10.1002/cam4.4085 |
| work_keys_str_mv | AT fangyunan abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT yugu abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT zijunxu abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT guokangsun abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT jingdongzhou abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT tingjuanzhang abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT jichunma abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT jiayanleng abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT jianglin abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia AT junqian abnormalexpressionandmethylationofprr34as1areassociatedwithadverseoutcomesinacutemyeloidleukemia |